Orally administrated cinnamon extract reduces β-amyloid oligomerization and corrects cognitive impairment in Alzheimer's disease animal models

PLoS One. 2011 Jan 28;6(1):e16564. doi: 10.1371/journal.pone.0016564.

Abstract

An increasing body of evidence indicates that accumulation of soluble oligomeric assemblies of β-amyloid polypeptide (Aβ) play a key role in Alzheimer's disease (AD) pathology. Specifically, 56 kDa oligomeric species were shown to be correlated with impaired cognitive function in AD model mice. Several reports have documented the inhibition of Aβ plaque formation by compounds from natural sources. Yet, evidence for the ability of common edible elements to modulate Aβ oligomerization remains an unmet challenge. Here we identify a natural substance, based on cinnamon extract (CEppt), which markedly inhibits the formation of toxic Aβ oligomers and prevents the toxicity of Aβ on neuronal PC12 cells. When administered to an AD fly model, CEppt rectified their reduced longevity, fully recovered their locomotion defects and totally abolished tetrameric species of Aβ in their brain. Furthermore, oral administration of CEppt to an aggressive AD transgenic mice model led to marked decrease in 56 kDa Aβ oligomers, reduction of plaques and improvement in cognitive behavior. Our results present a novel prophylactic approach for inhibition of toxic oligomeric Aβ species formation in AD through the utilization of a compound that is currently in use in human diet.

MeSH terms

  • Administration, Oral
  • Alzheimer Disease / drug therapy
  • Alzheimer Disease / prevention & control*
  • Amyloid beta-Peptides / drug effects*
  • Animals
  • Cinnamomum zeylanicum*
  • Cognition Disorders / drug therapy*
  • Cognition Disorders / prevention & control
  • Diptera
  • Disease Models, Animal
  • Mice
  • Mice, Transgenic
  • Protein Multimerization / drug effects
  • Treatment Outcome

Substances

  • Amyloid beta-Peptides